# OnCo record nct06423911 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06423911/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06423911", "NCT06423911" ;
  schema:name "Study of Olverembatinib (HQP1351) in Patients With CML-CP"@en ;
  schema:alternateName "POLARIS-2"@en ;
  schema:description "A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06423911/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06423911> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-02-05" ;
  onco:cancers <https://onco.cc/cancers/cml/>, <https://onco.cc/cancers/cml-chronic-phase/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/olverembatinib/> ;
  onco:companies <https://onco.cc/companies/ascentage-pharma/> .